Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Xeris Biopharma Holdings Inc shares valued at $119,610 were sold by PERSKY MARLA on Sep 11 ’25. At $7.72 per share, PERSKY MARLA sold 15,500 shares. The insider’s holdings dropped to 142,000 shares worth approximately $1.32 million following the completion of this transaction.
Also, MARLA PERSKY purchased 15,500 shares, netting a total of over 121,055 in proceeds.
Before that, SHERMAN JEFFREY W had sold 42,232 shares from its account. In a trade valued at $334,515, the Director traded Xeris Biopharma Holdings Inc shares for $7.92 each. Upon closing the transaction, the insider’s holdings decreased to 42,232 shares, worth approximately $2.03 million.
Analysts at Piper Sandler downgraded the stock from ‘”an Overweight”‘ to ‘”a Neutral”‘ outlook in a report released in mid November. As of March 28, 2024, Oppenheimer has initiated its “an Outperform” rating for XERS. Earlier on August 28, 2023, Craig Hallum initiated its rating. Their recommendation was “a Buy” for XERS stock.
Analyzing XERS Stock Performance
On last trading session, Xeris Biopharma Holdings Inc [NASDAQ: XERS] rose 14.16% to $9.27. The stock’s lowest price that day was $8.13, but it reached a high of $9.29 in the same session. During the last five days, there has been a surge of approximately 13.05%. Over the course of the year, Xeris Biopharma Holdings Inc shares have jumped approximately 218.56%.
Is Xeris Biopharma Holdings Inc subject to short interest?
Stocks of Xeris Biopharma Holdings Inc saw a sharp rise in short interest on 2025-09-30 jumping by 2.73 million shares to 17.44 million. Data from Yahoo Finance shows that the short interest on 2025-08-29 was 14.71 million shares. A jump of 15.64% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.7 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.7.
Which companies own the most shares of Xeris Biopharma Holdings Inc (XERS)?
In terms of Xeris Biopharma Holdings Inc share price expectations, FactSet research, analysts set an average price target of 5.75 in the next 12 months, down nearly -29.19% from the previous closing price of $8.12. Analysts anticipate Xeris Biopharma Holdings Inc stock to reach 6.6 by 2025, with the lowest price target being 4. In spite of this, 3 analysts ranked Xeris Biopharma Holdings Inc stock as Buy at the end of 2025. On October 21, 2022, Jefferies assigned a price target of “a Buy” to the stock and initiated coverage with a $4.
